| Not Yet Recruiting | Phase 4, Double-blind Study Evaluating the Response on Computed Tomography (CT) Lung Density Decline Rates of Alpha1 Antitrypsin Deficiency, Alpha1-Proteinase Inhibitor Deficiency, Emphysema | Phase 4 | 2026-04-15 |
| Recruiting | Safety of Anumigilimab (CSL324) in Adults With Sickle Cell Disease (SCD) Sickle Cell Disease | Phase 2 | 2026-02-02 |
| Recruiting | Efficacy and Safety of Vamifeport in Adult Participants With Homeostatic Iron Regulator Gene (HFE)-Related Her Homeostatic Iron Regulator Gene-related Hereditary Hemochromatosis | Phase 2 | 2026-01-22 |
| Recruiting | Efficacy and Safety of 4F-PCC (4-Factor Prothrombin Complex Concentrate) in Adult Patients Undergoing Complex Complex Cardiovascular Surgery With Cardiopulmonary Bypass | Phase 3 | 2025-09-15 |
| Recruiting | Dose Range Finding, Efficacy, and Safety Study of Nebulized CSL787 in Adults With Non-cystic Fibrosis Bronchie Non-cystic Fibrosis Bronchiectasis | Phase 2 | 2025-09-03 |
| Recruiting | Phase 3, Open-label, Single-dose Study of CSL222 in Adolescent Male Subjects (≥ 12 to < 18 Years of Age) With Hemophilia B | Phase 3 | 2025-07-28 |
| Recruiting | A Study Investigating the Effectiveness and Safety of Garadacimab for Treating Patients With Hereditary Angioe Hereditary Angioedemas | — | 2025-07-21 |
| Recruiting | An Open-label, Multicenter Study to Assess the Pharmacokinetics (PK), Safety, and Tolerability of Subcutaneous Primary Immunodeficiency | Phase 4 | 2025-07-15 |
| Recruiting | Safety, Efficacy, and Pharmacokinetics of CSL889 in Adults and Adolescents With Sickle Cell Disease During Vas Sickle Cell Disease Vaso-occlusive Crisis | Phase 2 | 2025-07-10 |
| Completed | Effect of Food on the Oral Bioavailability of a Prolonged-release Formulation of Vamifeport in Healthy Adults Healthy Volunteers | Phase 1 | 2025-05-27 |
| Recruiting | Safety Study in Subjects ≥ 12 Years of Age With Hereditary Angioedema Switching to Garadacimab Hereditary Angioedema | Phase 4 | 2025-03-19 |
| Recruiting | Recombinant Single-chain Factor VIII (rVIII-SingleChain) in Chinese Participants With Hemophilia A Previously Congenital Hemophilia A | Phase 3 | 2025-01-09 |
| Completed | Pharmacokinetics and Pharmacodynamics of Two Prolonged-release Formulations of Vamifeport in Healthy Adults Healthy Volunteers | Phase 1 | 2024-11-22 |
| Recruiting | Phase 3 Study of Fibrinogen Concentrate (CSL511) in Subjects With Pseudomyxoma Peritonei Undergoing Cytoreduct Acquired Fibrinogen Deficiency | Phase 3 | 2024-10-01 |
| Terminated | Double-blind, Randomized, Placebo-controlled Study Evaluating Efficacy and Safety of IgPro20 in Post-COVID-19 Post-COVID Postural Orthostatic Tachycardia Syndrome | Phase 3 | 2024-08-28 |
| Active Not Recruiting | Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Chinese Subjects With Hemoph Hemophilia B | Phase 3 | 2024-07-28 |
| Recruiting | Efficacy and Safety of CSL222 (Etranacogene Dezaparvovec) Gene Therapy in Adults With Hemophilia B With Pretre Hemophilia B | Phase 3 | 2024-01-30 |
| Completed | First-In-Human Study To Evaluate The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Escalatin Complement-mediated Disorders | Phase 1 | 2023-09-28 |
| Enrolling By Invitation | Long-term Follow-up Study of Male Adults With Hemophilia B Previously Treated With Etranacogene Dezaparvovec ( Hemophilia B | — | 2023-08-30 |
| Recruiting | An Observational Cohort Study to Characterize the Effectiveness and Safety of HEMGENIX® in Patients With Hemop Hemophilia B | — | 2023-06-15 |
| Completed | CSL312_3003 Safety and Pharmacokinetic Study in Subjects 2 to 11 Years of Age With Hereditary Angioedema Hereditary Angioedema (HAE) | Phase 3 | 2023-05-30 |
| Terminated | Evaluation of BE1116 in Patients With Traumatic Injury and Acute Major Bleeding to Improve Survival ( TAP Stud Traumatic Injury | Phase 3 | 2023-03-28 |
| Completed | Effects of CSL324 in the Lung After Segmental Challenge Healthy Volunteers | Phase 1 | 2022-12-20 |
| Recruiting | Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Atherosclerotic Cardiovascular Disease, End Stage Kidney Disease, Atherosclerotic Cardiovascular Disease in Patients With ESKD | Phase 2 / Phase 3 | 2022-10-21 |
| Completed | Assess Burden of Disease Among Kidney Transplant Recipients With Chronic Active Antibody Mediated Rejection Antibody-mediated Rejection in Kidney Transplant | — | 2022-07-14 |
| Recruiting | Hizentra® in Inflammatory Neuropathies - pHeNIx Study Chronic Inflammatory Demyelinating Polyneuropathy | — | 2022-06-10 |
| Completed | A Study to Compare the Pharmacokinetics of CSL312 Administered by Prefilled Syringe Assembled to Autoinjector Healthy Participants | Phase 1 | 2022-04-04 |
| Completed | Garadacimab Safety, Pharmacokinetics, and Pharmacodynamics in Idiopathic Pulmonary Fibrosis Idiopathic Pulmonary Fibrosis | Phase 2 | 2022-02-03 |
| Active Not Recruiting | Observatory of Patients With Haemophilia B Treated by IdElvion® Haemophilia B | — | 2021-12-03 |
| Completed | Safety of Single Doses of CSL889 in Adult Patients With Sickle Cell Disease Sickle Cell Disease | Phase 1 | 2021-05-20 |
| Completed | Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema A Hereditary Angioedema | Phase 3 | 2021-04-29 |
| Active Not Recruiting | Study of AAV5-hFIX in Severe or Moderately Severe Haemophilia B Hemophilia B | — | 2021-03-18 |
| Terminated | Pharmacokinetics, Safety, and Tolerability of CSL760, an Intravenous Anti-SARS-CoV-2 Hyperimmune Globulin, in Coronavirus Disease 2019 (COVID-19) | Phase 1 | 2021-02-02 |
| Completed | CSL312 (Garadacimab) in the Prevention of Hereditary Angioedema Attacks Hereditary Angioedema | Phase 3 | 2021-01-27 |
| Completed | Study to Assess CSL787 in Non-cystic Fibrosis Bronchiectasis (NCFB) Noncystic Fibrosis Bronchiectasis (NCFB) | Phase 1 | 2020-12-07 |
| Completed | A Study to Assess the Pharmacokinetics and Safety of CSL312 in Healthy Japanese and Caucasian Adults Healthy Volunteers | Phase 1 | 2020-10-29 |
| Completed | Pharmacokinetics and Safety of Subcutaneous CSL324 in Healthy Japanese and White Subjects Healthy | Phase 1 | 2020-10-08 |
| Terminated | Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneous CSL730 in Healthy Ad Immune Complex-mediated Autoimmune Diseases | Phase 1 | 2020-09-23 |
| Completed | Vascular Endothelial Growth Factor-B (VEGF-B) Blockade With the Monoclonal Antibody CSL346 in Subjects With Di Diabetic Kidney Disease (DKD) | Phase 2 | 2020-09-14 |
| Withdrawn | CSL324 in COVID-19 Coronavirus Disease 2019 (COVID-19) | Phase 2 | 2020-09-01 |
| Completed | Treatment With CSL312 in Adults With Coronavirus Disease 2019 (COVID-19) Coronavirus Disease 2019 (COVID-19) | Phase 2 | 2020-07-01 |
| Withdrawn | A Clinical Study to Test the Efficacy and Safety of CSL312 on Catheter-associated Blood Clot Formation in Subj PICC-associated Thrombosis | Phase 1 / Phase 2 | 2020-03-01 |
| Completed | Treatment of GVHD in Hematopoietic Stem Cell Transplant (HSCT) Recipients Using AAT Plus Corticosteroids (CS) Graft Versus Host Disease (GVHD) | Phase 3 | 2020-01-09 |
| Withdrawn | Efficacy and Safety of IgPro10 in Adults With Systemic Sclerosis (SSc) Diffuse Cutaneous Systemic Sclerosis | Phase 2 | 2019-12-20 |
| Completed | A Clinical Study to Test the Safety, Exposure, and Pharmacodynamic Markers of CSL311 in Patients With Mild-to- Asthma | Phase 1 | 2019-11-28 |
| Terminated | A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 in Adults With Dermatomyositis (DM) Dermatomyositis | Phase 3 | 2019-10-21 |
| Completed | Respreeza® Self-administration and Learning Program (AmAREtTI Study) Alpha-1 Antitrypsin Deficiency | — | 2019-10-18 |
| Terminated | Clazakizumab for the Treatment of Chronic Active Antibody Mediated Rejection in Kidney Transplant Recipients Antibody-mediated Rejection | Phase 3 | 2019-10-14 |
| Terminated | CSL200 Gene Therapy in Adults With Severe Sickle Cell Disease Anemia, Sickle Cell | Phase 1 | 2019-10-02 |
| Completed | Safety and Pharmacokinetics of IgPro20 and IgPro10 in Adults With Systemic Sclerosis (SSc) Diffuse Cutaneous Systemic Sclerosis | Phase 2 | 2019-09-19 |
| Completed | Safety and Pharmacokinetics of Repeat Doses of CSL324 in Subjects With Hidradenitis Suppurativa and Palmoplant Hidradenitis Suppurativa, Palmoplantar Pustulosis | Phase 1 | 2019-07-04 |
| Active Not Recruiting | The Safety and Efficacy of Alpha-1 Antitrypsin (AAT) for the Prevention of Graft-versus-host Disease (GVHD) in Acute-graft-versus-host Disease | Phase 2 / Phase 3 | 2019-03-27 |
| Recruiting | Two Dose Levels of Privigen in Pediatric CIDP Pediatric Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) | Phase 4 | 2019-02-28 |
| Completed | A Study to Investigate CSL312 in Subjects With Hereditary Angioedema (HAE) Hereditary Angioedema | Phase 2 | 2018-10-29 |
| Completed | Register of Patients With haEmophilia A tReated With Afstyla® Haemophilia A | — | 2018-09-24 |
| Completed | Dose Confirmation Trial of AAV5-hFIXco-Padua Hemophilia B | Phase 2 | 2018-07-24 |
| Completed | HOPE-B: Trial of AMT-061 in Severe or Moderately Severe Hemophilia B Patients Hemophilia B | Phase 3 | 2018-06-27 |
| Completed | Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome Acute Coronary Syndrome | Phase 3 | 2018-03-21 |
| Terminated | Assessing the Safety and Tolerability of CSL730 in Healthy Caucasian and Japanese Adults Healthy | Phase 1 | 2018-01-10 |
| Terminated | Evaluating the Effectiveness of Telemonitoring System in the Management of Patients With CIDP Chronic Inflammatory Demyelinating Polyneuropathy | — | 2017-11-27 |
| Terminated | Efficacy and Safety of Human Plasma-derived C1-esterase Inhibitor as add-on to Standard of Care for the Treatm Antibody-mediated Rejection | Phase 3 | 2017-11-06 |
| Completed | Safety and Tolerability of Higher Infusion Parameters of IgPro20 (Hizentra) in Subjects With Primary Immunodef Primary Immunodeficiency | Phase 4 | 2017-02-01 |
| Completed | A Study of CSL112 in Adults With Moderate Renal Impairment and Acute Myocardial Infarction Acute Myocardial Infarction, Moderate Renal Impairment | Phase 2 | 2016-08-01 |
| Completed | Study of Immune Deficiency Patients Treated With Subcutaneous Immunoglobulin (IgPro20, Hizentra®) on Weekly an Primary Immune Deficiency, Secondary Immune Deficiency | Phase 4 | 2016-03-15 |
| Completed | Registry of Patients With Von WilLEbrand Disease Treated With Voncento® Von Willebrand Disease | — | 2015-11-23 |
| Completed | Study of Voncento® in Subjects With Von Willebrand Disease Von Willebrand Disease | Phase 4 | 2015-10-05 |
| Terminated | Study of Recombinant Factor VIIa Fusion Protein (rVIIa-FP, CSL689) for On-demand Treatment of Bleeding Episode Hemophilia A With Inhibitors, Hemophilia B With Inhibitors | Phase 2 / Phase 3 | 2015-07-23 |
| Completed | Study of the Pharmacokinetics and Safety of Recombinant Factor VIIa Fusion Protein (rVIIa-FP, CSL689) in Patie Congenital Coagulation Factor VII Deficiency | Phase 1 | 2015-07-01 |
| Completed | Trial of AAV5-hFIX in Severe or Moderately Severe Hemophilia B Hemophilia B | Phase 1 / Phase 2 | 2015-06-10 |
| Completed | An Observational Cohort Study of the Safety and Efficacy of Fibrinogen Concentrate, Human (FCH) in Subjects Wi Congenital Fibrinogen Deficiency | — | 2015-05-07 |
| Completed | A Study of CSL112 in Healthy Adults and in Adults With Moderate Renal Impairment Acute Myocardial Infarction | Phase 1 | 2015-05-01 |
| Completed | A Study to Evaluate the Long-term Clinical Safety and Efficacy of Subcutaneously Administered C1-esterase Inhi Hereditary Angioedema Types I and II | Phase 3 | 2014-12-31 |
| Completed | An Open-label Safety and Efficacy Study of Recombinant FVIII in Patients With Severe Hemophilia A Hemophilia A, Severe Hemophilia A | Phase 3 | 2014-10-13 |
| Completed | Study of a Prothrombin Complex Concentrate for Rapid Reversal of Coagulopathy Induced by Vitamin K Antagonists Acute Major Bleeding, Reversal of Coagulopathy | Phase 3 | 2014-10-01 |
| Completed | A Phase 2b Study of CSL112 in Subjects With Acute Myocardial Infarction. Acute Myocardial Infarction | Phase 2 | 2014-08-01 |
| Completed | Extension Study of Maintenance Treatment With Subcutaneous Immunoglobulin (IgPro20) for Chronic Inflammatory D Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Polyradiculoneuropathy, Chronic Inflammatory Demyelinating | Phase 3 | 2014-07-30 |
| Completed | An Observational Cohort Study to Investigate the Risk of Thromboembolic Events in Patients Receiving Kcentra® Hemorrhage | — | 2014-04-24 |
| Completed | Pharmacokinetic, Efficacy, and Safety Study of Recombinant Factor VIII Single Chain (rVIII-SingleChain) in Chi Congenital Hemophilia A | Phase 3 | 2014-03-01 |
| Completed | A Safety and Efficacy Extension Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Album Hemophilia B | Phase 3 | 2014-02-06 |
| Completed | A Study to Evaluate the Clinical Efficacy and Safety of Subcutaneously Administered C1-esterase Inhibitor in t Hereditary Angioedema Types I and II | Phase 3 | 2014-01-01 |
| Completed | A Safety, Efficacy and Pharmacokinetics Study of a Recombinant Fusion Protein Linking Coagulation Factor IX Wi Hemophilia B | Phase 3 | 2013-01-01 |
| Completed | A Study to Evaluate the Safety and Pharmacokinetics of Two Formulations of C1-esterase Inhibitor Hereditary Angioedema Types I and II | Phase 1 | 2013-01-01 |
| Terminated | Study of Biostate for Treatment of Children With Hemophilia A Complicated by Antibody Development Hemophilia A | Phase 3 | 2012-12-01 |
| Completed | Phase IIB Dose Ranging Study in Subjects With Moderate to Severe Rheumatoid Arthritis Rheumatoid Arthritis | Phase 2 | 2012-06-01 |
| Terminated | Dose Ranging Study of BMS-945429 in Subjects With Moderate to Severe Crohn's Disease Crohn's Disease | Phase 2 | 2012-06-01 |
| Completed | A Study to Evaluate the Clinical Pharmacology and Safety of C1-esterase Inhibitor Administered by the Subcutan Hereditary Angioedema Types I and II | Phase 1 / Phase 2 | 2012-04-01 |
| Terminated | Exploratory Safety Study of ALD518 in Subjects With Steroid-refractory Acute Graft Versus Host Disease (GVHD) Acute GvHD | Phase 1 / Phase 2 | 2012-03-01 |
| Completed | Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Treatment With Subcutaneous Immunoglobulin (IgPro Chronic Inflammatory Demyelinating Polyneuropathy, Polyradiculoneuropathy | Phase 3 | 2012-03-01 |
| Completed | A Safety and Pharmacokinetics Study of a Recombinant Fusion Protein Linking Coagulation Factor VIIa With Album Healthy | Phase 1 | 2012-03-01 |
| Completed | An Open-label Safety, Efficacy and Pharmacokinetic Study of a Recombinant FVIII Compared to Recombinant Human Hemophilia A | Phase 2 / Phase 3 | 2012-02-01 |
| Completed | A Safety and Efficacy Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP Hemophilia B | Phase 2 / Phase 3 | 2012-02-01 |
| Completed | Study of Fibrinogen Concentrate (Human) (FCH) to Control Bleeding During Complex Cardiovascular Surgery Surgical Blood Loss, Postoperative Blood Loss | Phase 3 | 2012-01-01 |
| Completed | Psoriatic Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to NSAIDs or Non-biol Arthritis, Psoriatic | Phase 2 | 2011-12-01 |
| Completed | A Safety Study of Intravenous Immunoglobulin in Patients With Chronic Immune Thrombocytopenic Purpura (ITP) Immune Thrombocytopenic Purpura | Phase 4 | 2011-11-01 |
| Completed | Postmarketing Immunogenicity Study in HAE Subjects Treated With Berinert Hereditary Angioedema Types I and II | Phase 4 | 2011-11-01 |
| Completed | Multicenter Study of Long-Term Clinical Outcomes of Subcutaneous Immune Globulin IgPro20 in Subjects With Prim Primary Immune Deficiency | Phase 3 | 2011-10-01 |
| Terminated | Safety and Efficacy of ALD518 for Reducing Oral Mucositis in Head and Neck Cancer Subjects Oral Mucositis | Phase 2 | 2011-07-01 |
| Completed | A Safety and Efficacy Study of a Recombinant Factor IX in Patients With Severe Hemophilia B Hemophilia B | Phase 1 / Phase 2 | 2011-07-01 |
| Completed | Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotr Rheumatoid Arthritis | Phase 2 | 2011-06-01 |
| Completed | Safety and Tolerability Study of Liquid Alpha1 Proteinase Inhibitor (API) in Subjects With Cystic Fibrosis Cystic Fibrosis | Phase 1 | 2011-04-01 |
| Completed | Follow-up Study of Subcutaneous Immune Globulin in Patients Requiring IgG Replacement Therapy (Japan Study) Primary Immune Deficiency Disorder | Phase 3 | 2011-04-01 |
| Completed | Study of Efficacy and Safety of Privigen in Subjects With Chronic Inflammatory Demyelinating Polyneuropathy Chronic Inflammatory Demyelinating Polyneuropathy | Phase 3 | 2010-11-01 |
| Completed | Extension Study of Biostate in Subjects With Von Willebrand Disease Von Willebrand Disease | Phase 3 | 2010-10-01 |
| Completed | Safety and Pharmacokinetic Study of a Recombinant Coagulation Factor IX Albumin Fusion Protein in Subjects Wit Hemophilia B | Phase 1 | 2010-10-01 |
| Completed | Study of Subcutaneous Immune Globulin in Patients Requiring IgG Replacement Therapy (Japan Study) Primary Immune Deficiency | Phase 3 | 2010-09-01 |
| Completed | Study of Biostate® in Children With Von Willebrand Disease Von Willebrand Disease | Phase 3 | 2010-08-01 |
| Completed | Study of Biostate® in Children With Hemophilia A Hemophilia A | Phase 3 | 2010-08-01 |
| Completed | Observational Study of Prophylaxis and Treatment of Acute Perioperative Bleeding With Beriplex® P/N (Probe Stu Coagulation Protein Disorders, Blood Loss, Surgical, Perioperative Care | — | 2010-05-01 |
| Completed | Retrospective Chart Review of Subcutaneous IgG Use in Infants Primary Immune Deficiency | — | 2010-05-01 |
| Completed | Patient Registry Study of Berinert® in Normal Clinical Practice Includes: Hereditary Angioedema | — | 2010-04-01 |
| Completed | Quality of Life Study of Helixate NexGen Hemophilia A | — | 2010-01-01 |
| Completed | Health Related Quality of Life of Youth and Young Adults With Hemophilia A Hemophilia A | — | 2009-10-01 |
| Withdrawn | Fibrinogen Concentrate (Human) - Efficacy and Safety Study Afibrinogenemia, Hypofibrinogenemia, Fibrinogen Deficiency | Phase 3 | 2009-10-01 |
| Completed | An Open Enrollment Study of Factor XIII Concentrate in Subjects With Congenital Factor XIII Deficiency Factor XIII Deficiency | Phase 3 | 2009-09-01 |
| Completed | A Study of Factor XIII Concentrate in Subjects With Congenital Factor XIII Deficiency Factor XIII Deficiency | Phase 3 | 2009-08-01 |
| Completed | Study of a pd VWF/FVIII Concentrate, Biostate®, in Subjects With Von Willebrand Disease Von Willebrand Disease | Phase 2 / Phase 3 | 2009-06-01 |
| Completed | A Study of the Use of Factor XIII Concentrate in Patients With Inherited FXIII Deficiency Factor XIII Deficiency | Phase 2 | 2009-05-01 |
| Completed | An Open-label, Randomized, Multicenter Phase IIIb Study to Assess the Efficacy, Safety and Tolerance of BERIPL Reversal of Coagulopathy | Phase 3 | 2009-02-01 |
| Completed | Study of a pd vWF/FVIII, Biostate®, in Subjects With Haemophilia A Hemophilia A | Phase 2 | 2009-02-01 |
| Completed | Rabies Immune Plasma Booster Study Rabies | — | 2009-01-01 |
| Completed | Safety, Efficacy and Pharmacokinetics Study of ALD518 in Patients With Active Rheumatoid Arthritis Arthritis, Rheumatoid | Phase 2 | 2008-10-01 |
| Completed | Safety, Efficacy and Pharmacokinetics of ALD518 in Patients With Non-Small Cell Lung Cancer-related Fatigue an NSCLC, Fatigue, Cachexia | Phase 2 | 2008-09-01 |
| Completed | Study of Subcutaneous Immune Globulin in Patients Requiring IgG Replacement Therapy (EU Extension Study) Primary Immunodeficiency (PID) | Phase 3 | 2008-08-01 |
| Completed | Efficacy and Safety Study of BERIPLEX® P/N (Kcentra) Compared With Plasma in Patients With Acute Major Bleedin Blood Coagulation Disorders, Acute Major Bleeding | Phase 3 | 2008-06-01 |
| Completed | Extension Study of Subcutaneous Immunoglobulin Human in Patients With Primary Immunodeficiency (PID) Primary Immune Deficiency | Phase 3 | 2008-06-01 |
| Completed | Haemocomplettan® P During Aortic Replacement Aortic Aneurysm | Phase 2 | 2008-06-01 |
| Completed | Extension Study of Zemaira® i.v. Administration in Subjects With Emphysema Due to alpha1-proteinase Inhibitor Emphysema, Alpha 1-proteinase Inhibitor Deficiency | Phase 4 | 2008-04-01 |
| Completed | A Canadian Study to Assess the Safety of Humate-P® Ivr (Infusion Volume Reduced) Von Willebrand Disease | — | 2008-02-01 |
| Completed | A Study of Purified Human Antibodies Administered Subcutaneously to Patients With Multifocal Motor Neuropathy Multifocal Motor Neuropathy (MMN) | Phase 2 | 2007-11-01 |
| Completed | Study of Subcutaneous Immune Globulin in Patients Requiring IgG Replacement Therapy Common Variable Immunodeficiency, X-linked Agammaglobulinemia, Autosomal Recessive Agammaglobulinemia | Phase 3 | 2007-09-01 |
| Completed | Human Fibrinogen - Pharmacokinetics Fibrinogen Deficiency | Phase 2 | 2007-07-01 |
| Completed | Efficacy and Safety of Vivaglobin® in Previously Untreated Patients With Primary Immunodeficiency Common Variable Immunodeficiency, Agammaglobulinemia | Phase 4 | 2007-03-01 |
| Completed | Study of Subcutaneous Immunoglobulin in Patients With PID Requiring IgG Replacement Therapy Primary Immune Deficiency | Phase 3 | 2006-11-01 |
| Completed | Zemaira in Subjects With Emphysema Due to Alpha1-Proteinase Inhibitor Deficiency Alpha1-proteinase Inhibitor Deficiency, Emphysema | Phase 4 | 2006-03-01 |
| Completed | Safety and Efficacy of Intravenous Immunoglobulin IgPro10 in Patients With Primary Immunodeficiencies (PID) Agammaglobulinemia, IgG Deficiency, Common Variable Immunodeficiency | Phase 3 | 2005-11-01 |
| Completed | Prothrombin Complex Concentrate for Anticoagulant Reversal Acquired Coagulation Factor Deficiency | Phase 3 | 2005-09-01 |
| Completed | C1 Esterase Inhibitor in Hereditary Angioedema (HAE)(Extension Study) Hereditary Angioedema | Phase 3 | 2005-08-01 |
| Completed | Human C1 Esterase Inhibitor (C1-INH) in Subjects With Acute Abdominal or Facial Hereditary Angioedema (HAE) At Hereditary Angioedema | Phase 2 / Phase 3 | 2005-06-01 |
| Completed | Treatment of Chronic Immune Thrombocytopenic Purpura (ITP) With Intravenous Immunoglobulin IgPro10 Immune Thrombocytopenic Purpura | Phase 3 | 2004-12-01 |
| Completed | Efficacy and Safety of Intravenous Immunoglobulin IVIG-F10 in Patients With Primary Immunodeficiencies (PID) Agammaglobulinemia, IgG Deficiency, Common Variable Immunodeficiency | Phase 3 | 2004-09-01 |
| Completed | Efficacy and Safety of Intravenous Immunoglobulin IgPro10 in Patients With Primary Immunodeficiencies (PID) Agammaglobulinemia, IgG Deficiency, Common Variable Immunodeficiency | Phase 3 | 2004-09-01 |
| Completed | Study of Safety and Efficacy of Antihemophilic Factor/Von Willebrand Factor Complex in Surgical Subjects With Von Willebrand Disease, Blood Coagulation Disorders, Blood Platelet Disorders | Phase 4 | 2001-10-01 |
| Available | Post Study Access of CSL312 (Garadacimab) for Pediatric Participants With Hereditary Angioedema Who Have Compl Hereditary Angioedema (HAE) | — | — |